By james art 
Australian drug cannabis developer is ready to establish its operations in the UK in Acceleration Acceleration Accelerations (PHTA) by Birmingham.
Cannim, founded in 2017, treats products from the entire network of manufacturers for the development of medical cannabis through research and development.
It will be based in the first building to be completed at the University of Birmingham Health Innovation Campus of Birmingham (BHIC), containing 130,000 square feet, developed by Bruntwood in partnership with the University, BHIC will become a worldwide hub HUB life science Hub.
Partnership with PHTA will focus on expanding the understanding of the endocannabinoid system, a physiological system that helps maintain balance in the body. Kanam says that phytocannabinoids (compounds found in the cannabis plant) have shown a promise to treat various conditions such as chronic pain, stress and sleep disorders, interacting with this system.
A series of observation clinical trials will be launched, initially focusing on veterans suffering from PTSD. These studies will lay the foundations for future randomized controlled tests aimed at a more ongoing study of the therapeutic potential of medical cannabis. The study will also extend to women’s health problems, such as dysmenorrhea and menopause, as well as age -related conditions such as Alzheimer’s.
The partnership seeks to pioneer so -called civil scientific model, where patients provide valuable feedback on how drug cannabis affects their health and well -being.
Stewart Marsh, CEO of CHIM growth and graduate of the University of Birmingham, said: “We are excited to cooperate with PHTA and the University of Birmingham to further explore the transformative potential of drug cannabis.
“By combining our scientific expertise with the university’s avant-garde research, we strive to improve the patient’s results and build a complete understanding of how cannabis can best be used to treat a number of conditions.”
Professor Anup Matthew, Medical Director of the Lumir Clinic, said: “Our goal is not only to provide evidence -based solutions for the needy, but also to destroy the barriers around the stigma of the drug cannabis.
“We are committed to guaranteeing that both healthcare professionals and patients have access to the latest research and treatments.”
Professor Gino Martini, CEO of PHTA, said: “This partnership emphasizes the unique role of the University of Birmingham and PHTA as leaders in medical research, bringing together academic circles and industry to deal with important gaps in the knowledge of drug cannabis and its potential to improve the improvement of Life.
“Cannim and PHTA are excited to move forward on this initiative, positioning Birmingham as a future research center for medical cannabis and cannabinoid studies in the UK and beyond.”